A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE) (NCT07058012)
A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab and Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy
🩺 Plain-English Summary (8th-Grade Level)
The NSABP FC-13 study is being done to determine if using immunotherapies alone or in combination with other drugs will delay or prevent colorectal cancer from coming back in patients with colorectal cancer who are ctDNA-positive after their treatment. Immunotherapeutic drugs (immunotherapies) act on different proteins on the surface of cells of the immune system and trigger the immune system to destroy cancer cells. The drugs being studied in NSABP FC-13 are cemiplimab, fianlimab, and REGN7075.
Who can join: Review the eligibility criteria below.
Location: University of Florida — Gainesville, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (9 Sites)
- University of Florida — Gainesville, Florida
- University of Iowa - Holden Comprehensive Cancer Center — Iowa City, Iowa
- University of Kansas Cancer Center — Kansas City, Kansas
- Missouri Baptist — St Louis, Missouri
- First Health of the Carolinas — Pinehurst, North Carolina
- Allegheny General Hospital — Pittsburgh, Pennsylvania
- Ballad Health Cancer Center - Kingsport — Kingsport, Tennessee
- Bon Secours St. Francis Medical Center — Midlothian, Virginia
- Virginia Commonwealth University - Massey — Richmond, Virginia
📞 Contact the Study Coordinator
Phone: (800) 270-3165
Email: industry.trials@nsabp.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Colo-rectal Cancer
- EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer — Buffalo, New York
- Decision Counseling and Follow-up for Shield+ Patients — Philadelphia, Pennsylvania
- Eliminating Barriers to Colorectal Cancer Screening Using Rapid Cycle Testing: A Pilot Study — Boston, Massachusetts
- Colorectal Cancer Screening Outreach — New Haven, Connecticut
- Evaluation of SINGLE PORT (SP) Robotic Technology in Colorectal Surgery — Sacramento, California
Explore by condition: All Colo-rectal Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.